Patrick G Enright bought $18.3M of Veradermics (MANE)
Executed Feb 5, disclosed Feb 6, the same day.
Over the 21 trading sessions from the disclosed entry session (Feb 5), the stock returned +27.0% (delay-adjusted); from the execution session (Feb 5), +27.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Patrick G Enright (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Vera Therapeutics, Inc. (VERA). Across 3 priced purchase filings, the average 21-session return was +18.6% from execution and +20.1% from disclosure (delay-adjusted; derived). The largest single filing was $18.3M of MANE (1,075,000 sh across 2 lots, as filed), executed Feb 5.
Healthcare · Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthe…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→